Related SPY Tiki Barber Talks About His Biggest Financial Blunder And Why He Started Thuzio S&P 500 Index Futures Lower In Choppy Session The Way Forward For Hedge Funds (Seeking Alpha) Related S&P 500 Index Futures Lower In Choppy Session S&P 500 Index Futures Flat In Quiet Trading
S&P 500 index futures are trading higher by 2 points at 2089.25 in Thursday's session. The index is having one of its quietest sessions since April 25, when it had a 11.75 point range. Including the premarket, the index is trading in only a 9.25 range, compared with its nine-day average of 22 points.
Most of the session has had the index grinding between the close (2087.25) and 2090.
Posted-In: Futures Technicals Intraday Update Markets Trading Ideas
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Top Paper Stocks To Own Right Now: Oasis Petroleum Inc.(OAS)
Oasis Petroleum Inc., an independent exploration and production company, focuses on the acquisition and development of unconventional oil and natural gas resources in the North Dakota and Montana regions of the Williston Basin. Its principal projects are located in West Williston and East Nesson. As of December 31, 2015, the company had 484,745 net leasehold acres in the Williston Basin; and approximately 218.2 million barrels of oil equivalent of estimated net proved reserves. It sells its oil and natural gas to refiners, marketers, and other purchasers that have access to pipeline and rail facilities. The company was founded in 2007 and is headquartered in Houston, Texas.
- [By Robert Rapier]
Oasis Petroleum (OAS) is a pure Bakken/Three Forks play, with 335,000 leased acres in the Williston Basin.
Oasis has only been a public company since 2010, and in addition to the $400 million raised in its initial public offering, the company has funded operations with $1.2 billion in debt.
- [By Ben Levisohn]
The $50/Bbl Question Is Answered In our June 2nd note entitled, Rethinking Risk/Reward on High Beta E&Ps, we highlighted that $50/Bbl is a critical level as it is around which many E&Ps have indicated they would begin either utilizing drilled-but-uncompleted (DUC) wells and/or increasing activity. Thus, with the NYMEX strip exceeding ~$50/Bbl in H216 and 2017, the question becomes, What will E&Ps do next? In our note we distinguished which oilier SMID Caps could organically accelerate at current NYMEX strip prices without further leveraging the balance sheet and which would still require higher oil prices. We ranked WPX third, behindOasis Petroleum (OAS) and Whiting Petroleum (WLL) in terms of its ability to accelerate through the drill-bit while keeping the balance sheet intact. For WPX we concluded that without increasing activity beyond our base case assumptions or higher oil prices, leverage would increase by 0.8x in 2017. However with accelerated activity and corresponding higher outspend (via more Williston DUCs and an addtl Permian rig), we forecast WPX could further grow production next year and keep leverage flattish at ~3.5x Net Debt/EBITDAX. We think todays announcements confirm our thesis, as WPX increased 2016 Williston activity and issued equity to facilitate this addtl spend plus potential activity acceleration in 2017/2018 without adding more debt.
Top Paper Stocks To Own Right Now: National Grid Transco, PLC(NGG)
National Grid plc, incorporated on July 11, 2000, is an electricity and gas utility company focused on transmission and distribution activities in electricity and gas in both the United Kingdom and the United States. The Company’s segments include UK Electricity Transmission, which is engaged in high voltage electricity transmission networks in Great Britain; UK Gas Transmission, which is the gas transmission network in Great Britain and UK liquefied natural gas (LNG) storage activities; UK Gas Distribution, which includes approximately four of the eight regional networks of Great Britain’s gas distribution system, and US Regulated, which includes gas distribution networks, electricity distribution networks and high voltage electricity transmission networks in New York, and New England and electricity generation facilities in New York. Its other activities relate to non-regulated businesses and other commercial operations not included within the above segments, including t he United Kingdom gas metering activities; the Great Britain-France Interconnector; the United Kingdom property management; a United Kingdom LNG import terminal (National Grid Grain LNG Limited); the United States LNG operations; the United States unregulated transmission pipelines; together with corporate activities.
UK Electricity Transmission
The Company owns and operates the electricity transmission network in England and Wales, with day-to-day responsibility for balancing supply and demand. The Company operates but do not own the Scottish networks. Its networks comprise approximately 7,200 kilometers (over 4,470 miles) of overhead line, approximately 1,500 kilometers (over 930 miles) of underground cable and approximately 340 substations.
UK Gas Transmission
The Company owns and operates the gas national transmission system in Great Britain, with day-to-day responsibility for balancing supply and demand. Its network co mprises approximately 7,660 kilometers (over 4,760 miles) of! high pressure pipe and approximately 20 compressor stations. The gas throughput across the system is over 80 billion cubic meters.
UK Gas Distribution
The Company owns and operates approximately four gas distribution networks comprising over 131,000 kilometers (over 81,400 miles) of pipeline. The Company transports gas from the national transmission system to approximately 10.9 million consumers on behalf of approximately 40 shippers.
The Company jointly owns and operates transmission facilities across upstate New York, Massachusetts, New Hampshire, Rhode Island and Vermont. It owns and operates electricity distribution networks in upstate New York, Massachusetts and Rhode Island. The assets it operates include over 170 kilometers (approximately 110 miles) of underground cable, over 490 transmission substations and approximately 690 distribution substations. It owns and operates gas distribution networks acros s the northeastern United States, located in upstate New York, New York City, Long Island, Massachusetts and Rhode Island. The Company forecasts, plans for and procures over 20 billion standard cubic meters of gas each year.
- [By Paul R. La Monica]
And the infrastructure fund has stakes in cell phone tower owners Crown Castle (CCI) and SBA Communications (SBAC), as well as giant British gas and electric utility National Grid (NGG).
Best Building Product Stocks To Watch For 2016: SORL Auto Parts Inc.(SORL)
SORL Auto Parts, Inc., through its principal operating subsidiary, Ruili Group Ruian Auto Parts Co., Ltd., engages in the development, manufacture, and distribution of automotive brake systems and other safety related auto parts for commercial vehicles, such as trucks and buses. The company, through its 90% ownership in Ruili Group Ruian Auto Parts Co., Ltd., a Sino-foreign joint venture, offers various products, including spring brake chamber, clutch servos, air dryers, relay valves, and hand brake valves. It also provides auto metering products, auto electric products, anti-lock brake systems, retarders, hydraulic brakes, and power steering products. SORL Auto Parts, Inc. markets its products under the SORL brand to automotive original equipment manufacturers and the related aftermarket customers in the People?s Republic of China and internationally. The company was founded in 2003 and is headquartered in Ruian City, the People?s Republic of China.
- [By Monica Gerson]
Sorl Auto Parts, Inc. (NASDAQ: SORL) is expected to post its quarterly earnings at $0.20 per share on revenue of $55.35 million.
Clean Diesel Technologies, Inc. (NASDAQ: CDTI) is projected to post a quarterly loss at $0.18 per share on revenue of $10.25 million.
Top Paper Stocks To Own Right Now: BioDelivery Sciences International Inc.(BDSI)
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, focuses on developing and commercializing products in the areas of pain management and oncology supportive care. The company uses its patented BioErodible MucoAdhesive (BEMA) and Bioral cochleate drug delivery technologies in the development of its products. The BEMA technology is a small erodible polymer film for application to the buccal mucosa; and the Bioral cochleate drug delivery technology encapsulates a selected drug or therapeutic in a cochleate cylinder. Its pain franchise consists of products utilizing the patented BEMA technology, including ONSOLIS, a fentanyl buccal soluble film for the management of pain in opioid tolerant adult patients with cancer; and BEMA Buprenorphine, which is in the development stage for the treatment of moderate to severe chronic pain, as well as for the treatment of opioid dependence. The company also engages in developing product candidates utilizing the B EMA technology for conditions, such as nausea/vomiting. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.
- [By Lisa Levin]
In trading on Friday, healthcare shares fell by 0.62 percent. Meanwhile, top losers in the sector included Akorn, Inc. (NASDAQ: AKRX), down 17 percent, and BioDelivery Sciences International, Inc. (NASDAQ: BDSI), down 14 percent.
Top Paper Stocks To Own Right Now: Celgene Corporation(CELG)
Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID to treat multiple myeloma; and OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, ankylosing spondylitis, Beh莽et’s disease, atopic dermatitis, and ulcerative colitis. The companys products also include VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); THALOMID for the patients with multiple myeloma and erythema nodosum leprosum; ISTODAX to treat cutaneous and peripheral T-cell lymphoma; and F OCALIN, FOCALIN XR, and RITALIN products. Its clinical stage products include OTEZLA for the treatment of various immune-inflammatory diseases; sotatercept for the treatment of renal anemia, beta-thalassemia and MDS; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; PDA-002 for the treat diabetic foot ulcers and peripheral neuropathy; and PNK-007 for hematological malignancies treatment. The company has collaborative agreements with Novartis Pharma AG; Acceleron Pharma; Agios Pharmaceuticals, Inc.; Epizyme Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; Acetylon Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; and Triphase Accelerator Corporation, as well as a strategic collaboration with Nurix, Inc. The company was founded in 1980 and is headquartered in Summit, New Jersey.
- [By Ben Levisohn]
Do we need to remind you how hard biotech stocks have been hit this year? If you read this blog, probably not, but we’ll do it anyway. The iShares Nasdaq Biotechnology ETF (IBB) has fallen 24%, while Gilead Sciences (GILD) has declined 8.7%, Biogen (BIIB) has fallen 17%, Celgene (CELG) has dropped 16%, and Regeneron Pharmaceuticals (REGN) has plunged 32%. Yet despite these drops–and the decline in valuation that accompanied them–the Janus Equity Team contends nothing has changed for the sector:
- [By Ben Levisohn]
The S&P 500 gained 1.1% to 2,066.66 today, while the Dow Jones Industrial Average advanced 112.73 points, or 0.6%, to 17,716.05. The Nasdaq Composite rose 1.6% to 4,920.72, as Vertex Pharmaceuticals (VRTX), Celgene (CELG), and Endo Pharmaceuticals (ENDP) soared.